Disease · MONDO_0002407

capillary hemangioma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. capillary hemangioma. Diseases, record MONDO_0002407. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0002407

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: capillary hemangioma; Open Targets
Open Targets ID: MONDO_0002407; Open Targets
Other names: capillary angioma, capillary hemangioma (morphologic abnormality); Open Targets
Disease Ontology: DOID:2725; Disease Ontology
MeSH: D018324; MeSH
NCI Thesaurus: C7457; NCI Thesaurus
Highest stage of its drugs: Approval, for 1 of its 13 drugs, from PMDA; Open Targets

Drugs13

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
PROPRANOLOL HYDROCHLORIDE	CHEMBL1671	Small molecule	Approval	PMDA	1	0	0	Drugs and targets
PROPRANOLOL	CHEMBL27	Small molecule	Phase 3	ClinicalTrials.gov	11	11	11	Drugs and targets
TIMOLOL MALEATE	CHEMBL1200870	Small molecule	Phase 3	ClinicalTrials.gov	5	5	5	Drugs and targets
NADOLOL	CHEMBL521606	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
ACEBUTOLOL	CHEMBL642	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
ATENOLOL	CHEMBL24	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
PREDNISOLONE	CHEMBL131	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
IMIQUIMOD	CHEMBL1282	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
PREDNISONE	CHEMBL635	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
VINCRISTINE	CHEMBL90555	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 13

See all 13 drugs

Targets20

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ADRB1	Beta-1 adrenergic receptor	7	Beta-1 adrenergic receptor antagonist	Approval	https://conductscience.org/library/genes/153	Drugs and targets
ADRB2	Beta-2 adrenergic receptor	5	Beta-2 adrenergic receptor antagonist	Approval	https://conductscience.org/library/genes/154	Drugs and targets
NR3C1	Glucocorticoid receptor	2	Glucocorticoid receptor agonist	Phase 2	https://conductscience.org/library/genes/2908	Drugs and targets
HMGCR	3-hydroxy-3-methylglutaryl-coenzyme A reductase	1	HMG-CoA reductase inhibitor	Early phase 1	https://conductscience.org/library/genes/3156	Drugs and targets
TLR7	Toll-like receptor 7	1	Toll-like receptor 7 agonist	Phase 2	https://conductscience.org/library/genes/51284	Drugs and targets
TUBA1A	Tubulin	1	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	1	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	1	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	1	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/7278	Drugs and targets
TUBA3E	Tubulin	1	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/112714	Drugs and targets

1 to 10 of 20

See all 20 targets

Trials22

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02342275	Efficacy and Safety of Propranolol Versus Atenolol on the Proliferative Phase of Infantile Hemangioma	Phase 3	377	2022-06-16	Hemangioma	ATENOLOL, PROPRANOLOL	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT01074437	Corticosteroids With Placebo Versus Corticosteroids With Propranolol Treatment of Infantile Hemangiomas (IH)	Phase 2	9	2013-09-26	Hemangioma	PREDNISOLONE, PROPRANOLOL	Open Targets' reading of its record	ClinicalTrials.gov
NCT00555464	Clinical Trial of Vincristine vs. Prednisolone for Treatment of Complicated Hemangiomas	Phase 2	8	2013-06-11	Hemangioma	PREDNISOLONE, VINCRISTINE	Open Targets' reading of its record	ClinicalTrials.gov
NCT01147601	Topical Timolol 0.5% Solution for Proliferating Infantile Hemangiomas	Early phase 1	6	2017-07-05	Hemangioma, Infant	TIMOLOL	Open Targets' reading of its record	ClinicalTrials.gov
NCT07104526	Low-Dose Propranolol and Bleomycin for Infantile Hemangioma (IH)	Not applicable	260		Infantile Hemangioma (IH)	BLEOMYCIN, PROPRANOLOL	Open Targets' reading of its record	ClinicalTrials.gov
NCT06677853	Timolol Maleate Gel for the Treatment of Infantile Hemangioma	Phase 2/3	168		Infantile Hemangioma	TIMOLOL MALEATE	Open Targets' reading of its record	ClinicalTrials.gov
NCT03842631	Optimizing Timolol Maleate Treatment of Infantile Hemangioma by Doppler Ultrasound Examination		150		Infantile Hemangioma	TIMOLOL MALEATE	Open Targets' reading of its record	ClinicalTrials.gov
NCT04651049	Systemic Propranolol for the Treatment of Paediatric Patients With Infantile Hemangiomas		128		Infantile Haemangiomas	PROPRANOLOL	Open Targets' reading of its record	ClinicalTrials.gov
NCT02505971	Nadolol Versus Propranolol in Children With Infantile Hemangiomas	Phase 3	74		Infantile Hemangioma	NADOLOL, PROPRANOLOL	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT01211080	Off Label Use of Propranolol for Infancy Hemangiomas		72		Hemangioma	PROPRANOLOL	Open Targets' reading of its record	ClinicalTrials.gov

1 to 10 of 22

See all 22 trials

Comparisons in its trials10

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Propranolol vs Atenolol: Successful Initial Response	171 of 190	163 of 187	377	NCT02342275	Trial comparisons
Propranolol vs Atenolol: The Primary Outcome Measure Was Any Response at 6 Months	178 of 190	173 of 187	377	NCT02342275	Trial comparisons
Propranolol vs Atenolol: deaths from any cause	0 of 190	0 of 187	377	NCT02342275	Trial comparisons
Propranolol vs Atenolol: Number of Participants With Complete/Nearly Complete Response (96 Week)	156 of 190	149 of 187	377	NCT02342275	Trial comparisons
Propranolol vs Atenolol: serious adverse events	5 of 190	3 of 187	377	NCT02342275	Trial comparisons
Propranolol vs Atenolol: Rebound Rate	19 of 170	12 of 160	330	NCT02342275	Trial comparisons
Group A: Corticosteroid With Placebo vs Group B: Corticosteroid With Propranolol: serious adverse events	0 of 4	0 of 5	9	NCT01074437	Trial comparisons
Vincristine Treatment Group vs Oral Steroid Treatment Group: serious adverse events	0 of 4	0 of 4	8	NCT00555464	Trial comparisons
Topical 0.5% Timolol vs Placebo: serious adverse events	0 of 5	0 of 1	6	NCT01147601	Trial comparisons
Topical 0.5% Timolol vs Placebo: Proportion of Subjects in Treatment Group Compared to Placebo Group With at Least 75% Improvement in the Extent of the Hemangioma as Compared to Baseline Photos.	1 of 2	0 of 1	3	NCT01147601	Trial comparisons

Papers from its trials7

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
29571951	RESULT	1	PubMed
26813215	RESULT	1	PubMed
26021855	RESULT	1	PubMed
23301692	RESULT	1	PubMed
34747977	DERIVED	1	PubMed
33856430	DERIVED	1	PubMed
19419474	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0002407

GET https://conductscience.org/api/diseases/v1/MONDO_0002407/trials?page=2

API reference For AI assistants